Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Artemetherlumefantrine

Research Leaders

13 sponsors active, led by Centers for Disease Control and Prevention

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 3 (1)
Phase 4 (1)

Trial Status

Completed3
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06962319Phase 3Recruiting

Safety of Antimalarials in the FIRst trimEster

NCT06970600Not ApplicableCompletedPrimary

Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique

NCT00140361Phase 4CompletedPrimary

Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria

NCT00153491CompletedPrimary

Adherence to Lumefantrine-Artemether

Showing all 4 trials

Research Network

Common Treatments

  • Artemetherlumefantrine2
  • Sleeping Under Insecticidetreated Bednet1
  • Sulfadoxinepyrimethamine Plus Artesunate1
  • Pyronaridineartesunate Pa1
  • Artemetherlumefantrine Coartem1

Active Sponsors

  • Centers for Disease Control and Prevention2
  • Liverpool School of Tropical Medicine1
  • Malaria Research and Training Center, Bamako, Mali1
  • Ifakara Health Research and Development Centre1
  • Medicines for Malaria Venture (co-sponsor)1

Top Investigators

Related Conditions

  • Malaria Antepartum1
  • Malaria Pregnancy1

Activity Timeline